Cargando…
Adenoviruses as vaccine vectors
Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems fo...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Gene Theraphy. Published by Elsevier Inc.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106330/ https://www.ncbi.nlm.nih.gov/pubmed/15451446 http://dx.doi.org/10.1016/j.ymthe.2004.07.013 |
_version_ | 1783512590113046528 |
---|---|
author | Tatsis, Nia Ertl, Hildegund C.J. |
author_facet | Tatsis, Nia Ertl, Hildegund C.J. |
author_sort | Tatsis, Nia |
collection | PubMed |
description | Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. Additionally, they are being explored as vaccines against a multitude of tumor-associated antigens. In this review we describe the molecular biology of adenoviruses as well as ways the adenovirus vectors can be manipulated to enhance their efficacy as vaccine carriers. We describe methods of evaluating immune responses to transgene products expressed by adenoviral vectors and discuss data on adenoviral vaccines to a selected number of pathogens. Last, we comment on the limitations of using human adenoviral vectors and provide alternatives to circumvent these problems. This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens. |
format | Online Article Text |
id | pubmed-7106330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | The American Society of Gene Theraphy. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71063302020-03-31 Adenoviruses as vaccine vectors Tatsis, Nia Ertl, Hildegund C.J. Mol Ther Article Adenoviruses have transitioned from tools for gene replacement therapy to bona fide vaccine delivery vehicles. They are attractive vaccine vectors as they induce both innate and adaptive immune responses in mammalian hosts. Currently, adenovirus vectors are being tested as subunit vaccine systems for numerous infectious agents ranging from malaria to HIV-1. Additionally, they are being explored as vaccines against a multitude of tumor-associated antigens. In this review we describe the molecular biology of adenoviruses as well as ways the adenovirus vectors can be manipulated to enhance their efficacy as vaccine carriers. We describe methods of evaluating immune responses to transgene products expressed by adenoviral vectors and discuss data on adenoviral vaccines to a selected number of pathogens. Last, we comment on the limitations of using human adenoviral vectors and provide alternatives to circumvent these problems. This field is growing at an exciting and rapid pace, thus we have limited our scope to the use of adenoviral vectors as vaccines against viral pathogens. The American Society of Gene Theraphy. Published by Elsevier Inc. 2004-10 2016-12-14 /pmc/articles/PMC7106330/ /pubmed/15451446 http://dx.doi.org/10.1016/j.ymthe.2004.07.013 Text en Copyright © 2004 The American Society of Gene Theraphy. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tatsis, Nia Ertl, Hildegund C.J. Adenoviruses as vaccine vectors |
title | Adenoviruses as vaccine vectors |
title_full | Adenoviruses as vaccine vectors |
title_fullStr | Adenoviruses as vaccine vectors |
title_full_unstemmed | Adenoviruses as vaccine vectors |
title_short | Adenoviruses as vaccine vectors |
title_sort | adenoviruses as vaccine vectors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106330/ https://www.ncbi.nlm.nih.gov/pubmed/15451446 http://dx.doi.org/10.1016/j.ymthe.2004.07.013 |
work_keys_str_mv | AT tatsisnia adenovirusesasvaccinevectors AT ertlhildegundcj adenovirusesasvaccinevectors |